BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 26867783)

  • 21. Primary tumour ulceration in cutaneous melanoma: its role on TNM stages.
    Tas F; Erturk K
    Jpn J Clin Oncol; 2021 Feb; 51(2):192-198. PubMed ID: 33159197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in malignant melanoma - an immunohistochemical study.
    Salmi S; Lin A; Hirschovits-Gerz B; Valkonen M; Aaltonen N; Sironen R; Siiskonen H; Pasonen-Seppänen S
    BMC Cancer; 2021 May; 21(1):641. PubMed ID: 34051744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plantar melanoma is associated with certain poor prognostic histopathological factors, but not correlated with nodal involvement, recurrence, and worse survival.
    Tas F; Erturk K
    Clin Transl Oncol; 2018 May; 20(5):607-612. PubMed ID: 28948477
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Peritumoral Immune Infiltrate as a Prognostic Biomarker in Thin Melanoma.
    Sabbatino F; Scognamiglio G; Liguori L; Marra A; Anniciello AM; Polcaro G; Dal Col J; Caputo A; Peluso AL; Botti G; Zeppa P; Ferrone S; Pepe S
    Front Immunol; 2020; 11():561390. PubMed ID: 33117345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cell division cycle-associated protein 1 as a new melanoma-associated antigen.
    Tokuzumi A; Fukushima S; Miyashita A; Nakahara S; Kubo Y; Yamashita J; Harada M; Nakamura K; Kajihara I; Jinnin M; Ihn H
    J Dermatol; 2016 Dec; 43(12):1399-1405. PubMed ID: 27237743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nodular primary cutaneous melanoma is associated with PD-L1 expression.
    Giavina-Bianchi M; Giavina-Bianchi P; Sotto MN; Rodig S; Mihm M; Festa Neto C; Duncan LM; Kalil J
    Eur J Dermatol; 2020 Aug; 30(4):352-357. PubMed ID: 32969795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decreased expression of hyaluronan synthase 1 and 2 associates with poor prognosis in cutaneous melanoma.
    Poukka M; Bykachev A; Siiskonen H; Tyynelä-Korhonen K; Auvinen P; Pasonen-Seppänen S; Sironen R
    BMC Cancer; 2016 May; 16():313. PubMed ID: 27184066
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients.
    Donizy P; Zietek M; Halon A; Leskiewicz M; Kozyra C; Matkowski R
    Diagn Pathol; 2015 Jul; 10():86. PubMed ID: 26134500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Problems in defining melanoma regression and prognostic implication].
    Requena C; Botella-Estrada R; Traves V; Nagore E; Almenar S; Guillén C
    Actas Dermosifiliogr; 2009 Nov; 100(9):759-66. PubMed ID: 19889297
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma.
    Clemente CG; Mihm MC; Bufalino R; Zurrida S; Collini P; Cascinelli N
    Cancer; 1996 Apr; 77(7):1303-10. PubMed ID: 8608507
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival.
    Naffouje S; Naffouje R; Bhagwandin S; Salti GI
    Melanoma Res; 2015 Dec; 25(6):496-502. PubMed ID: 26317170
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FOXP3+ cell density in primary tumor has no prognostic impact in patients with cutaneous malignant melanoma.
    Ladányi A; Mohos A; Somlai B; Liszkay G; Gilde K; Fejos Z; Gaudi I; Tímár J
    Pathol Oncol Res; 2010 Sep; 16(3):303-9. PubMed ID: 20306313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The density and type of MECA-79-positive high endothelial venules correlate with lymphocytic infiltration and tumour regression in primary cutaneous melanoma.
    Avram G; Sánchez-Sendra B; Martín JM; Terrádez L; Ramos D; Monteagudo C
    Histopathology; 2013 Dec; 63(6):852-61. PubMed ID: 24102908
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study.
    Thomas NE; Busam KJ; From L; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Venn A; Kanetsky PA; Groben PA; Hao H; Orlow I; Reiner AS; Luo L; Paine S; Ollila DW; Wilcox H; Begg CB; Berwick M
    J Clin Oncol; 2013 Nov; 31(33):4252-9. PubMed ID: 24127443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastrointestinal stromal tumor markers in cutaneous melanomas: relationship to prognostic factors and outcome.
    Gonzalez RS; Carlson G; Page AJ; Cohen C
    Am J Clin Pathol; 2011 Jul; 136(1):74-80. PubMed ID: 21685034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic significance of the aberrant expression of neuroendocrine markers in melanomas.
    Wu Y; Lai Y; Zhang M; Li Z
    Diagn Pathol; 2021 Aug; 16(1):78. PubMed ID: 34454530
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer.
    Kroeger DR; Milne K; Nelson BH
    Clin Cancer Res; 2016 Jun; 22(12):3005-15. PubMed ID: 26763251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. De Novo vs Nevus-Associated Melanomas: Differences in Associations With Prognostic Indicators and Survival.
    Cymerman RM; Shao Y; Wang K; Zhang Y; Murzaku EC; Penn LA; Osman I; Polsky D
    J Natl Cancer Inst; 2016 Oct; 108(10):. PubMed ID: 27235387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FOXP3+ T regulatory lymphocytes in primary melanoma are associated with BRAF mutation but not with response to BRAF inhibitor.
    Leslie C; Bowyer SE; White A; Grieu-Iacopetta F; Trevenen M; Iacopetta B; Amanuel B; Millward M
    Pathology; 2015 Oct; 47(6):557-63. PubMed ID: 26308130
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Innate immune cell infiltration in melanoma metastases affects survival and is associated with BRAFV600E mutation status.
    Dabrosin N; Sloth Juul K; Bæhr Georgsen J; Andrup S; Schmidt H; Steiniche T; Heide Øllegaard T; Bønnelykke Behrndtz L
    Melanoma Res; 2019 Feb; 29(1):30-37. PubMed ID: 30299387
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.